Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:ADRO

Aduro Biotech (ADRO) Stock Price, News & Analysis

Aduro Biotech logo

About Aduro Biotech Stock (NASDAQ:ADRO)

Advanced Chart

Key Stats

Today's Range
N/A
50-Day Range
$2.28
$14.60
52-Week Range
N/A
Volume
171,500 shs
Average Volume
162,237 shs
Market Capitalization
$236.61 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Receive ADRO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Aduro Biotech and its competitors with MarketBeat's FREE daily newsletter.

ADRO Stock News Headlines

Aduro Clean Technologies Inc.
How to Collect Up To $5,917/mo From Trump’s Made In USA Boom
How to Collect Up To $5,917/mo From Trump's Made In USA Boom Thanks to President Trump's America-First policies, a historic wave of investment is flooding back into the United States: Apple committing a colossal $500 billion to build new U.S. factories. Microsoft injecting $80 billion into domestic manufacturing. Nvidia moving critical chip production back to America. But here's the hidden opportunity: There's now a groundbreaking way for you to start collecting monthly checks from these very same companies— checks that could reach as high as $5,917 each month. Don't miss your chance to participate directly in America's industrial comeback.
ACTHD Aduro Clean Technologies Inc.
Aduro Clean Technologies Inc Ordinary Shares
PT Adaro Energy Indonesia Tbk
PT Adaro Energy Indonesia Tbk ADRO
See More Headlines

ADRO Stock Analysis - Frequently Asked Questions

Aduro Biotech, Inc. (NASDAQ:ADRO) posted its quarterly earnings results on Monday, May, 4th. The biotechnology company reported ($0.09) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.14) by $0.05. The biotechnology company had revenue of $13.95 million for the quarter, compared to analyst estimates of $8.81 million. Aduro Biotech had a negative trailing twelve-month return on equity of 101.73% and a negative net margin of 230.92%.

Aduro Biotech (ADRO) raised $119 million in an IPO on Wednesday, April 15th 2015. The company issued 7,000,000 shares at a price of $17.00 per share. BofA Merrill Lynch and Leerink Partners served as the underwriters for the IPO and William Blair and Canaccord Genuity were co-managers.

Based on aggregate information from My MarketBeat watchlists, some other companies that Aduro Biotech investors own include Regulus Therapeutics (RGLS), Exact Sciences (EXAS), Flexion Therapeutics (FLXN), Paratek Pharmaceuticals (PRTK), Anavex Life Sciences (AVXL), VBI Vaccines (VBIV) and Amarin (AMRN).

Company Calendar

Last Earnings
5/04/2020
Today
7/03/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:ADRO
Fax
N/A
Employees
152
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$82.37 million
Net Margins
-230.92%
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$17.26 million
Price / Cash Flow
N/A
Book Value
$4.07 per share
Price / Book
N/A

Miscellaneous

Free Float
N/A
Market Cap
$236.61 million
Optionable
Optionable
Beta
0.40
Beginner's Guide To Retirement Stocks Cover

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

This page (NASDAQ:ADRO) was last updated on 7/3/2025 by MarketBeat.com Staff
From Our Partners